Immunotherapy drug shows promise for Hard-to-Treat brain tumors
NCT ID NCT03557359
First seen Nov 03, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study tested the drug nivolumab in 35 adults with a type of brain tumor (glioma) that has an IDH mutation and came back after previous treatment. The goal was to see if the drug could shrink the tumors. Nivolumab is an immunotherapy that helps the immune system fight cancer, but it is not a cure and ongoing management is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Miami Cancer Center
Miami, Florida, 33176, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.